title: Importance of endothelial function in mediating the benefits of lipid-lowering therapy.
abstract: Trials of lipid lowering by various methods have clearly demonstrated the benefits, clinically and angiographically. Evidence of slowed arterial disease progression and even regression has been convincing but modest, at best. For example, among those treated intensively in the Familial Atherosclerosis Treatment Study (FATS), the mean improvement in proximal stenosis severity was <1% per patient, and only 12% of all lesions showed convincing regression. Despite these modest arterial benefits, the associated reductions in major cardiovascular events have been surprisingly great (24-35% in 3 recent large trials and > or =50% in angiographic trials using combination therapies). The process of plaque disruption helps explain this discrepancy. Disruption can be predicted by a large accumulation of core lipid in the plaque and a high density of lipid-laden macrophages in its thinned fibrous cap. Lesions with these characteristics comprise only 10-20% of the overall lesion population but account for 60-90% of the acute clinical events. Lipid-lowering therapy has beneficial effects on these "high-risk" features of plaque morphology. The composite of data presented here supports the hypothesis that lipid-lowering therapy selectively depletes lipids from this relatively small but dangerous subgroup of fatty lesions, effectively stabilizing them.
authors.affiliation: Department of Medicine, University of Washington School of Medicine, Seattle 98195, USA.
authors.forename: B G
authors.initials: BG
authors.lastname: Brown
authors.forename: X Q
authors.initials: XQ
authors.lastname: Zhao
mesh_terms: D003324:Coronary Artery Disease / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D004730:Endothelium, Vascular / Q000502:physiology*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D000960:Hypolipidemic Agents / Q000627:therapeutic use*
chemical_list: D000960:Hypolipidemic Agents